Emeryville, CA. — Sep. 24, 2009
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will webcast an investor briefing on Wednesday, September 30, 2009, beginning at 10:00 a.m. Eastern Time. Speakers will review clinical data for Nexavar in breast cancer presented at the 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress in Berlin.
Interested parties may access a live webcast of the presentation on our website at:
or by dialing 847-413-3362 and using the passcode 25477763. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 25477763 approximately one hour after the teleconference concludes. The replay will be available through October 30, 2009.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar®, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company’s website at www.onyx-pharm.com.
Nexavar® (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.